Table 2 Uni and multivariable linear regression analysis of patient’s characteristics, years of exposure to antiretrovirals and trunk/limb fat mass ratio in 166 pts. with DEXA scan results
Risk factors | Univariablea regression coefficient [95% CI] | p-value | Multivariableb regression coefficient [95% CI] | p- Value |
|---|---|---|---|---|
Characteristics of individual and HIV infection | ||||
Age (per 10 years increase of age) | 0.24 [0.08;0.41] | 0.003 | – | – |
Sex (female compared to male) | −0.78 [−1.13; − 0.43] | < 0.001 | −0.83 [−1.15; − 0.51] | < 0.001 |
Years since HIV infection (per 10 years of infection duration) | 0.34 [0.13;0.55] | 0.002 | – | – |
Nadir CD4 (per 100 cells) | 0.02 [− 0.04;0.08] | 0.46 | – | – |
Immune parameters at time of dexa scan | ||||
CD4 at DEXA (per 100 cells) | 0.01 [−0.05;0.08] | 0.70 | – | – |
logViral load at DEXA test (per 1 log increase) | −0.7 [− 0.13; − 0.01] | 0.015 | −0.05 [− 0.11;0.00] | 0.058 |
Exposure to antiretrovirals (measured in years of exposure, coefficients for 10 years increase in cumulative use) | ||||
Zidovudine | 0.26 [−0.05;0.57] | 0.10 | 0.34 [0.06;0.62] | 0.018 |
Stavudine | 1.0 [0.41;1.59] | 0.001 | 0.92 [0.38;1.47] | 0.001 |
Abacavir | 0.00 [−0.41;0.41] | 1.0 | – | – |
Tenofovir | −0.05 [− 0.44;0.33] | 0.78 | – | – |
Lopinavir/r | − 0.20 [− 0.61;0.20] | 0.33 | – | – |
Atazanavir/ r | 0.11 [− 0.30;0.53] | 0.59 | – | – |
Draunavir/r | 0.31 [− 0.27;0.90] | 0.30 | – | – |
Ritonavir | 0.64 [0.12;1.17] | 0.017 | – | – |
Raltegravir | 0.71 [0.19;1.22] | 0.008 | 0.57 [0.10;1.05] | 0.019 |